LGNXZ
LIGAND PHARMACEUTICALS INC
Overview
Ligand Pharmaceuticals operates as a biopharmaceutical royalty company that acquires and monetizes royalty interests in mid- to late-stage development and commercial drug products, generating non-dilutive cash flows from a diversified portfolio of over 90 programs.
LIGAND PHARMACEUTICALS INC.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks LGNXZ's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.55 | $3.05 | -16.3% | -1.4% | -0.5% |
| Q4 FY2026 | $2.49 | $3.05 | -18.5% | +3.9% | +4.3% |
| Q3 FY2026 | $2.19 | $2.97 | -26.1% | -0.9% | -1.5% |
| Q2 FY2026 | $2.59 | $3.08 | -16.0% | -6.7% | -5.6% |
| Q1 FY2025 | $2.52 | $3.06 | -17.7% | +2.5% | +2.5% |
| Q4 FY2025 | $2.58 | $3.10 | -16.7% | +1.2% | +0.8% |
| Q3 FY2025 | $2.67 | $3.10 | -13.8% | -3.1% | -4.2% |
| Q2 FY2025 | $2.66 | $3.10 | -14.2% | +0.7% | -2.2% |
| Q1 FY2024 | $2.81 | $3.24 | -13.2% | +2.5% | +2.7% |
| Q4 FY2024 | $2.26 | $3.10 | -27.2% | -7.8% | -9.1% |
Guidance change history
Sample- Q1 FY2026Lowered2026-04-15
- Q4 FY2026Lowered2026-13-15
- Q3 FY2026Lowered2026-10-15
- Q2 FY2026Lowered2026-07-15
- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Todd C DavisCEO6 mo14 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance cut Q3 FY2026
- Octavio EspinozaCFO6 mo6 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- Andrew ReardonCLO & Secretary1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LGNXZ.
$ curl https://api.spokenalpha.com/v1/companies/LGNXZFAQ
Frequently asked about LGNXZ
Where can I find LIGAND PHARMACEUTICALS INC's (LGNXZ) earnings call transcripts?
Spoken Alpha indexes LGNXZ's earnings call transcripts at https://spokenalpha.com/companies/LGNXZ. Each call links to attributed speakers and parsed analyst Q&A. LIGAND PHARMACEUTICALS INC's own investor relations page is at https://investor.ligand.com/overview/default.aspx.